Scientific Strategy

Can we identify biological pathways that might be: 

• Targets for intervention? 
• Shared with other neurodegenerative diseases? 
• Used to stratify patients? 
• Used to facilitate clinical trials agnostic to existing clinical diagnostic categories?

How can we rapidly, repeatedly, and consistently measure cognitive function?

• Can we combine existing & new data to track aging and disease progression?
• Can we identify novels ways to predict and delay the conversion of mild cognitive impairment to Alzheimer’s disease?
• What factors influence or underpin speed of progression – can that information lead to novel treatment targets for slowing disease and or stratification for clinical trials? 

• Can we identify a range of non-invasively collected biomarkers for determining Alzheimer's Disease and Related Dementias (ADRD) progression?
• Can we assess the validity and reliability of proposed novel biomarkers and diagnostics?
• Can we define multimodal approaches for early detection and risk prediction (including digital and activities of daily living)?

• Can explainable AI help create models of low-level personalized risk factor interactions to help with early diagnosis of ADRDs?
• Are there lifestyle or behavioral changes that will pause or delay Alzheimer’s disease symptoms?

Can subtypes of Alzheimer’s disease be further defined based on biomarker data and clinical presentation?

• How are ADRD risk prediction models similar and different in LMICs compared to high-income countries?
• Are models for LMICs applicable across LMICs or different between countries?

Can we identify the risk determinants associated with ARIA?